Study DesignsPlacebo-controlled Studies

16

BL

Period 1 – Evaluation

Period 2 – Follow-up

4

Week 0

12

28

Screen

Placebo

Bosentan 125 mg bid

Placebo

62.5 mgbid

AC-052-351

AC-052-352

62.5 mgbid

Bosentan 250 mg bid

Screen

Placebo

Bosentan 125 mg bid

Placebo

62.5 mgbid

1º Endpoints

(Variable Period 2)

(Fixed Period 2 for pts

who participated)

9016.01

Previous slide

Next slide

Back to first slide

View graphic version